Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4333-4338

  Löwenberg, Bob ^a   Morgan, Gareth ^a   Ossenkoppele, Gert J ^a   Burnett, Alan K ^a   Zachée, Pierre ^a   Dührsen, Ulrich ^a   Dierickx, Daan ^a   Müller Tidow, Carsten ^a   Sonneveld, Pieter ^a   Krug, Utz ^a   Bone, Elisabeth ^a   Flores, Nicolas ^a   Richardson, Alison F ^a   Hooftman, Leon ^a   Jenkins, Chris ^a   Zweegman, Sonja ^a   Davies, Faith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; CHR 2797 001; CHR 79888; TOSEDOSTAT; UNCLASSIFIED DRUG; 2 (2 (HYDROXY(HYDROXYCARBAMOYL)METHYL) 4 METHYLPENTANOYLAMINO) 2 PHENYLETHANOIC ACID CYCLOPENTYL ESTER; 2-(2-(HYDROXY(HYDROXYCARBAMOYL)METHYL)-4-METHYLPENTANOYLAMINO)-2-PHENYLETHANOIC ACID CYCLOPENTYL ESTER; DRUG DERIVATIVE; GLYCINE; HYDROXAMIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINOPEPTIDASES; FEMALE; GLYCINE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 78049441128     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6295     Document Type: Article

References (9)

1. Saric T, Graef CI, Goldberg AL: Pathway for degradation of peptides generated by proteasomes: A key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279:46723-46732, 2004 (Pubitemid 39518320)
2. Krige D, Needham LA, Bawden LJ, et al: CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 68:6669-6679, 2008
3. Jenkins C, Mills K, Pepper C, et al: Cellular aminopeptidase inhibition as a target for the therapy of AML by the novel agent CHR-2797. Blood 110, 2007 (abstr 1608)
4. Reid AH, Protheroe A, Attard G, et al: A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res 15:4978-4985, 2009
5. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
6. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
7. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
8. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997 (Pubitemid 27337928)
9. Dent S, Zee B, Dancey J, et al: Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19:785-791, 2001 (Pubitemid 32119094)